Johnson & Johnson (JNJ)
154.42
-0.98
(-0.63%)
USD |
NYSE |
Dec 08, 16:00
154.43
+0.01
(+0.01%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 371.73B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -10.24% |
| Valuation | |
| PE Ratio | 11.46 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.782 |
| Price to Book Value | 5.219 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 1.19 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.4201 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 27.36% |
Profile
| Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States. |
| URL | https://www.jnj.com |
| Investor Relations URL | https://www.investor.jnj.com |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 23, 2024 |
| Last Earnings Release | Oct. 17, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 20, 2023 |
Ratings
Profile
| Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States. |
| URL | https://www.jnj.com |
| Investor Relations URL | https://www.investor.jnj.com |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 23, 2024 |
| Last Earnings Release | Oct. 17, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 20, 2023 |